Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Celltrion Prep For October Inflectra Launch

Executive Summary

With Celltrion shipping the first batch of its biosimilar Inflectra (infliximab-dyyb) and a stipulation agreement with Johnson & Johnson, Pfizer is set to launch the product on Oct. 3 – six months after it was approved in the US.


Related Content

Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Nixed Remicade Patent Clears Way For Pfizer/Celltrion Biosimilar Launch
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
Panel Favors Celltrion Biosimilar; Skeptical On Cost Savings
Novartis/Sandoz make history with 1st US biosimilar Zarxio


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts